Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs.

With Phagocure, our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.

Products, services, technology

We focus on high unmet medical need, devastating diseases with high morbidity, mortality & limited treatment options.

Phagocure our gene therapy platform allows targeted & safe CURE a wide range of  immunodeficiencies (lead program), neurological, neuro-metabolic & phagocytes related diseases.

Cooperation possibilities
  • Currently fund-raising for series A - interested in meeting investors
  • Open to strategic partnering - interested in meeting Pharma & Biotech to leverage internal R&D capabilities and deliver synergies for both companies.
Some insights

    The objective of Somagenetix is to provide a once in a lifetime treatment aiming at curing children and adults suffering from highly debilitating inherited genetic diseases that currently have limited options or no treatment available.

    I am proud of my company because the center of all our actions is the patients, how to accelerated the path to market and provide them with a treatment. It’s an honour to be a part of a team whose dedication to ethics and professionalism always comes through.

    My team is composed of seasoned academic professional experts in Cell and Gene therapy with a high level of knowledge and more importantly of experience in this field. We now need to integrate few people with industry background to complete & strengthen the team and professionalise our approach.

    My wife knows exactly as she's part of the pharma industry but for my kids ... "Dad is selling drugs to big Companies" :) ... well not exactly but maybe one day. I try to explain how all this works and how we are trying to cure the patients.

    For our small start-up Company being part of the Swiss ecosystem is very important to get access to the network, get introduced to Investors. It is also very valuable to share and benefit from other companies experience.

    At the moment, fund raising is our #1 priority and so Investors would be choice number one. Then, help on non-dilutive financing to get access to grants. After this, it could be of interest to get introduced to companies of our size or that just passed our stage to discuss & share experience.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in